AbbVie Inc. executives lowered their outlook for the quarter and year in a filing with the Securities and Exchange Commission late Friday, which cited research and development expenses and milestone p...
Tag: ABBV
CytomX shares surge more than 50% on Moderna partnership
CytomX Therapeutics Inc. CTMX, +7.19% shares soared more than 50% in the extended session Thursday after the small biotech company announced a partnership with Moderna Inc. MRNA, -2.17% CytomX shares ...
AbbVie Stock Slips as Sales Miss Expectations And Bigger Challenges Await.
Stock in AbbVie slipped after the drug company reported a higher profit than expected, while sales fell short. The revenue shortfall may have reminded investors of a challenge AbbVie (ticker: ABBV) fa...
Opinion: These 3 safe stocks yield more than 10-year Treasurys
After the volatility of early 2022 and the aggressive rate tightening by the Fed, there’s a return of chatter about the “Great Rotation” – that is, a broad move among investors to reduce exposure to g...
The Three ‘Kings’ of High Dividend Yield
Investors on the hunt for safe dividends should consider the Dividend Kings, a group of just 45 stocks that have increased their dividends for at least 50 consecutive years. Of the Dividend Kings, thr...
Weighed Down by Opioid Litigation, Endo International Files for Bankruptcy
Text size Dreamstime The generic drugmaker Endo International , which faces thousands of lawsuits related to its alleged role in the opioid crisis, filed for bankruptcy late Tuesday morning, while ann...
10 defensive stocks that can also provide you with growth and dividends over the long term
The S&P 500 Index has rallied 10% since June 22 from a deep decline, but there are different schools of thought about whether investors are out of the woods yet. Mark Hulbert has called the recent...
AbbVie Stock Slips After Earnings, Charge for Potential Opioid Deal
Text size AbbVie said it continues to expect adjusted diluted earnings of between $13.78 and $13.98 per share for the full fiscal year. Dreamstime The drugmaker AbbVie turned in quarterly earnings tha...
AbbVie’s Correction Appears to Be Over: Here’s Where the Stock Could Be Headed
AbbVie (ABBV) , the research-based biopharmaceutical company that was spun off from Abbott Laboratories (ABT) in 2013, has made an impressive move higher the past nine years. Recently, ABBV pulled ba...
Warren Buffett’s Berkshire Hathaway reveals new stakes in Paramount, Citigroup
OMAHA, Neb. — Warren Buffett’s company on Monday revealed all the investment moves it made in the first quarter, when it spent more than $51 billion on stocks. But Buffett had already shared the bigge...
We Have a New AbbVie Price Target After Our Previous One Was Reached
AbbVie (ABBV) is a research-based biopharmaceutical company that was spun off from Abbott Laboratories (ABT) a number of years ago. Its blockbuster drug Humira brought in billions. We reviewed the cha...
Stocks for the Recession That May—or May Not—Be Coming
Text size Exelon stock offers a little bit of offense to go with its defense. Dreamstime The yield curve briefly inverted this past week—and that’s a recession signal that is either like Paul Revere’s...
Invest in AbbVie? I’ve Made My Decision
Kind of like that bunny that keeps on going… pharmaceutical firm AbbVie (ABBV) , long a Sarge fave, and now one of the oldest continuous long positions on my book, keeps on going… higher. ...
The 5 Highest-Yielding Dividend Kings
Cash is king, economic treasure and financial successful retirement conceptual idea with gold metal … [+] crown on pile of 100 dollar bills isolated on white background Getty Dividend Kings are ...
AbbVie’s stock gains on fourth-quarter earnings as it reports better-than-expected sales of Humira
An earlier version of this report referred to Humana in the headline, not Humira. It has been corrected. Shares of AbbVie Inc. ABBV, +0.08% gained 1.4% in premarket trading on Wednesday after the comp...
Biotech Stocks Are Due to Bounce Back. This One Stands Out.
Text size Large-cap biotech will offer a smoother ride than small, and Vertex, in particular, looks attractive. Igor Akimov/Dreamstime.com Biotech stocks began the year in much the same way they ended...
These 15 Dividend Aristocrat stocks have been the best income builders
The S&P Dividend Aristocrats deserve more coverage. Those are companies that have raised their dividend payouts consistently over the years — they’re dividend royalty, as it were. As a group, they...